
About Myra Vision
Myra Vision is a Healthcare company based in Campbell (United States) founded in 2019. Nanotechnology-based devices for glaucoma treatment are developed. Myra Vision has raised $42 million across 2 funding rounds from investors including PA MedTech VC Fund, Cormorant and Capital Partnership. Its chief executive, as recorded, is Robert Chang. Myra Vision offers products and services including Calibreye TGT Surgical System. Its focus areas include Life Sciences, Ophthalmology, Medical Devices and Therapy. Its legal entity is Myra Vision Inc. Its competitors include Glaukos, Ivantis and Transcend Medical; 3 of its 3 listed competitors have raised funding.
Company details
Myra Vision was founded in 2019 and is based in Campbell, United States. A medical device utilizing nanotechnology is developed for glaucoma management in the healthcare sector. Intraocular pressure is reduced by the device to address moderate to severe cases. Operations center on device innovation, with leadership provided by CEO Robert Chang. The domain myravision.com is maintained for company information.
- Headquarters Campbell, United States
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website myravision.com
- Social LinkedIn
- Legal Name Myra Vision Inc
- Total Equity Funding$42M (USD)
in 2 rounds
- Latest Funding Round$25M (USD), Series B
Jun 2023
- InvestorsCormorant
& 5 more
Products & Services of Myra Vision
Myra Vision offers a comprehensive portfolio of products and services, including Calibreye TGT Surgical System.
Adjustable system for controlling intraocular pressure in glaucoma patients.
Funding Insights of Myra Vision
Myra Vision has successfully raised a total of $42M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $25 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $42M
- Total Rounds 2
- Last Round Series B β $25M
- First Round $17M
(Jun 2021)
- Investors Count 6
All 2 funding rounds of Myra Vision with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2023 | $25M | Series B | β | PA MedTech VC Fund, Cormorant Asset Management | |
| Jun 2021 | $17M | Series A | β | The Capital Partnership |
6 investors in total: 6 institutional.
Investors in Myra Vision
Myra Vision has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include PA MedTech VC Fund, Cormorant and Capital Partnership.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
An asset management and investment platform is operated by The Capital Partnership. | tcpam.com | London, United Kingdom | ||
Medical technology innovation hub focused on device development in Silicon Valley. | 2001 | shifamed.com | ||
Manages diversified investment portfolios across various asset classes. | 1997 | cormorant.com | Boston, United States | |
Sourcing and deploying capital for real estate investments and developments. | cormorant-capital.com | New York, United States | ||
Real estate consulting services are provided by Capital Partnership. | capital-partnership.co.jp | Tokyo, Japan |
Investor details for Myra Vision
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Myra Vision
9 people are tracked at Myra Vision (5 in leadership, 4 in team).
| Name | Role | Group |
|---|---|---|
Robert Chang | CEO | Leadership |
Signe Erickson | Chief Operating Officer | Leadership |
Brock Gause | Director Of Operations | Leadership |
Claudio Argento | CTO - Co-Founder | Leadership |
Rick Iribarren | Senior Director Of Operations | Leadership |
Katherine Sapozhnikov | Senior R&D Engineer | Team |
Nicholas Dubil | Associate Production Engineer | Team |
Michael Heck | Senior Process Development Engineer | Team |
Abigail Brazil | Research And Development Engineer | Team |
Complete people profiles for Myra Vision
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Myra Vision
3 dated milestones of Myra Vision across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Myra Vision is founded.
- Funding First funding round of $17.0M.
- Funding Latest funding round, Series B, of $25.0M.
Competitors of Myra Vision
Myra Vision has 3 listed competitors in our database, 3 of them funded. They include Glaukos, Ivantis and Transcend Medical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| glaukos.com | 2001 | Laguna Hills, United States | $117.57M | 907 | Developer of implants to treat glaucoma | |
| ivantisinc.com | 2007 | Irvine, United States | $166.23M | 132 | Implantable device to relieve intraocular pressure in open angle glaucoma | |
| transcendmedical.com | 2006 | Menlo Park, United States | $122.27M | 20 | Minimally invasive glaucoma stents are developed to enhance aqueous outflow. |
Detailed competitors of Myra Vision
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Ophthalmology
3 companies that operate in the same segment as Myra Vision (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 24.69 B | 25,941 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Myra Vision
Complete news archive for Myra Vision
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Myra Vision
Myra Vision was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Myra Vision is headquartered in Campbell, United States. It is registered at Campbell, California, United States.
Robert Chang is the CEO of Myra Vision, as recorded in our data.
Myra Vision is a funded company, having raised a total of $42M across 2 funding rounds to date. The company's 1st funding round was a Series A of $17M, raised on Jun 2021.
Myra Vision was founded in 2019 and is based in Campbell, United States. A medical device utilizing nanotechnology is developed for glaucoma management in the healthcare sector. Intraocular pressure is reduced by the device to address moderate to severe cases. Operations center on device innovation, with leadership provided by CEO Robert Chang. The domain myravision.com is maintained for company information.
Myra Vision's top competitors include Glaukos, Ivantis and Transcend Medical.
Myra Vision offers Calibreye TGT Surgical System.
Myra Vision has 6 investors. Key investors include PA MedTech VC Fund, Cormorant, Capital Partnership, The Capital Partnership, and Shifamed.
Myra Vision operates through Myra Vision Inc.
